Immunogenicity and safety of a 23-valent pneumococcal polysaccharide vaccine in chinese healthy population aged >2 years: A randomized, double-blinded, active control, phase III trial

Human Vaccines and Immunotherapeutics

Volumn 11, Issue 10, 2015, Pages 2425-2433

  Kong, Yujia ^a   Zhang, Wei ^a   Jiang, Zhiwei ^a   Wang, Ling ^a   Li, Chanjuan ^a   Li, Yanping ^b   Xia, Jielai ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention   (China)

Author keywords

Immunogenicity; Pneumococcal polysaccharide vaccine; Safety

Indexed keywords

ANTI PNEUMOCOCCAL ANTIBODY; BACTERIUM ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG; 23-VALENT PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE;

ANTIBODY RESPONSE; ARTICLE; BRONCHITIS; CHINESE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE SURVEILLANCE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; ENZYME LINKED IMMUNOSPOT ASSAY; FATIGUE; FEVER; GEOMETRIC MEAN CONCENTRATION; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MENINGITIS; MICROBIOLOGICAL PARAMETERS; MULTICENTER STUDY; NAUSEA; NEPHROLITHIASIS; NORMAL HUMAN; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SEROLOGY; STREPTOCOCCUS PNEUMONIA; THYROID DISEASE; THYROPHYMA; VACCINATION; ADOLESCENT; ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CHILD; CLINICAL TRIAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; MIDDLE AGED; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; STREPTOCOCCAL INFECTIONS; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, BACTERIAL; ASIAN CONTINENTAL ANCESTRY GROUP; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEALTHY VOLUNTEERS; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; PNEUMOCOCCAL VACCINES; STREPTOCOCCAL INFECTIONS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84953879079     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2015.1055429     Document Type: Article

References (48)

1. O’Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, Lee E, Mulholland K, Levine OS, Cherian T. Hib and pneumococcal global burden of disease study team; Hib and pneumococcal global burden of disease study team. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009; 374(9693):893-902; PMID:19748398; http://dx.doi.org/10.1016/S0140-6736(09)61204-6
2. Schrag SJ, Beall B, Dowell SF. Limiting the spread of resistant pneumococci: biological and epidemiologic evidence for the effectiveness of alternative interventions. Clin Microbiol Rev 2000; 13:588-601; PMID:11023959; http://dx.doi.org/10.1128/CMR.13.4.588-601.2000
3. Whitney CG, Farley MM, Hadler J, Harrison LH, Lexau C, Reingold A, Lefkowitz L, Cieslak PR, Cetron M, Zell ER, et al. Active Bacterial Core Surveillance Program of the Emerging Infections Program Network. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000; 343:1917-24; PMID:11136262; http://dx.doi.org/10.1056/NEJM200012283432603
4. McCormick AW, Whitney CG, Farley MM, Lynfield R, Harrison LH, Bennett NM, Schaffner W, Reingold A, Hadler J, Cieslak P, et al. Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States. Nat Med 2003; 9:424-30; PMID:12627227; http://dx.doi.org/10.1038/nm839
5. Bogaert D, de Groot R, Hermans PW. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis 2004; 4:144-54; PMID:14998500; http://dx.doi.org/10.1016/S1473-3099(04)00938-7
6. Hausdorff WP, Feikin DR, Klugman KP. Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis 2005; 5:83-93; PMID:15680778; http://dx.doi.org/10.1016/S1473-3099(05)01280-6
7. Type Study Group for Pneumococcus. Serotype study for Streptococcus pneumonia in 18 provinces, China. Chin J Epidemiol 1989; 10(3):133-7. [in Chinese]; PMID:2673527
8. Yao KH, Yang YH. Streptococcus pneumoniae diseases in Chinese children: past, present and future. Vaccine 2008; 26:4425-33; PMID:18602435; http://dx.doi.org/10.1016/j.vaccine.2008.06.052
9. Zhao GM, Black S, Shinefield H, Wang CQ, Zhang YH, Lin YZ, Lu JL, Guo YF, Jiang QW. Serotype distribution and antimicrobial resistance patterns in Streptococcus pneumoniae isolates from hospitalized pediatric patients with respiratory infections in Shanghai, China [J]. Pediatr Infect Dis J 2003; 22:739-42; PMID:12913778; http://dx.doi.org/10.1097/01.inf.0000078373.54515.40
10. Liu Y, Wang H, Chen M, Sun Z, Zhao R, Zhang L, Wang H, Zhang H, Wang L, Chu Y, et al. Serotype distribution and antimicrobial resistance patterns of Streptococcus pneumoniae isolated from children in China younger than 5 years. Diagn Microbiol Infect Dis 2008; 61:256-63; PMID:18358662; http://dx.doi.org/10.1016/j.diagmicrobio.2008.02.004
11. Xue L, Yao K, Xie G, Zheng Y, Wang C, Shang Y, Wang H, Wan L, Liu L, Li C, et al. Serotype distribution and antimicrobial resistance of Streptococcus pneumonia isolates that cause invasive disease among Chinese children. Clinical Infect Dis 2010; 50:741-4; http://dx.doi.org/10.1086/650534
12. Zhou L, Ma X, Gao W, Yao KH, Shen AD, Yu SJ, Yang YH. Molecular characteristics of erythromycin-resistant Streptococcus pneumoniae from pediatric patients younger than five years in Beijing, 2010. BMC Microbiol 2012; 12:228; PMID:23043378; http://dx.doi.org/10.1186/1471-2180-12-228
13. Ma X, Zhao R, Ma Z, Yao K, Yu S, Zheng Y, Yang Y. Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates causing invasive dis- eases from Shenzhen Children’s Hospital. PLoS One 2013; 8(6):e67507; PMID:23840728; http://dx.doi.org/10.1371/journal.pone.0067507
14. Zhao C, Zhang F, Chu Y, Liu Y, Cao B, Chen M, Yu Y, Liao K, Zhang L, Sun Z, et al. Phenotypic and genotypic characteristic of invasive Pneumococcal isolates from both children and adult patients from a multicenter surveillance in China 2005-2011. PLoS One 2013;8 (12):e82361; PMID:24349263; http://dx.doi.org/10.1371/journal.pone.0082361
15. Zhou L, Yu SJ, Gao W, Yao KH, Shen AD, Yang YH. Serotype distribution and antibiotic resistance of 140 pneumococcal isolates from pediatric patients with upper respiratory infections in Beijing, 2010. Vaccine 2011; (29):7704-10; PMID:21839135; http://dx.doi.org/10.1016/j.vaccine.2011.07.137
16. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson D, et al. Active bacterial core surveillance of the emerging infections program network. Decline in invasive pneumococcal disease after the introduction of protein polysaccharide conjugate vaccine. N Engl J Med 2003; 348:1737-46; PMID:12724479; http://dx.doi.org/10.1056/NEJMoa022823
17. Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, Reingold A, Thomas AR, Harrison LH, Bennett NM, Farley MM, et al. Active bacterial core surveillance of the emerging infections program network. Effect of the pneumococcal conjugate vaccine on drug- resistant Streptococcus pneumoniae. N Engl J Med 2006; 354:1455-63; PMID:16598044; http://dx.doi.org/10.1056/NEJMoa051642
18. Hanage WP, Huang SS, Lipsitch M, Bishop CJ, Godoy D, Pelton SI, Goldstein R, Huot H, Finkelstein JA. Diversity and antibiotic resistance among nonvaccine serotypes of Streptococcus pneumonia carriage isolates in the post-heptavalent conjugate vaccine era. J Infect Dis 2007; 195:347-52; PMID:17205472; http://dx.doi.org/10.1086/510249
19. Lexau CA, Lynfield R, Danila R, Pilishvili T, Facklam R, Farley MM, Harrison LH, Schaffner W, Reingold A, Bennett NM, et al. Active bacterial core surveillance team. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005; 294:2043-51; PMID:16249418; http://dx.doi.org/10.1001/jama.294.16.2043
20. Jansen AG, Rodenburg GD, van der Ende A, van Alphen L, Veenhoven RH, Spanjaard L, Sanders EA, Hak E. Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome. Clin Infect Dis 2009; 49(2):e23-9; PMID:19522653; http://dx.doi.org/10.1086/600045
21. Griffin MR, Zhu Y, Moore MR, Whitney CG, Grijalva CG. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med 2013; 369:155-63; PMID:23841730; http://dx.doi.org/10.1056/NEJMoa1209165
22. Dagan R. Impact of pneumococcal conjugate vaccine on infections caused by antibiotic-resistant Streptococcus pneumoniae. Clin Microbiol Infect 2009; 15(Suppl 3):16-20; PMID:19366365; http://dx.doi.org/10.1111/j.1469-0691.2009.02726.x
23. Burgos J, Falco V, Borrego A, Sorde R, Larrosa MN, Martinez X, Planes AM, Sanchez A, Palomar M, Rello J, et al. Impact of the emergence of non-vaccine pneumococcal serotypes on the clinical presentation and outcome of adults with invasive pneumococcal pneumonia. Clin Microbiol Infect 2013; 1:385-91; PMID:22583156; http://dx.doi.org/10.1111/j.1469-0691.2012.03895.x
24. Shapiro ED, Berg AT, Austrian R, Schroeder D, Parcells V, Margolis A, Adair RK, Clemens JD. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991; 21:1453-60; PMID:1944423; http://dx.doi.org/10.1056/NEJM199111213252101
25. Mangtani P, Cutts F, Hall AJ. Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: the state of the evidence. Lancet Infect Dis 2003; 3:71-8; PMID:12560191; http://dx.doi.org/10.1016/S1473-3099(03)00514-0
26. Vila-Corcoles A, Salsench E, Rodriguez-Blanco T, Ochoa-Gondar O, de Diego C, Valdivieso A, Hospital I, Gomez-Bertomeu F, Raga X. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case-control study. Vaccine 2009; 27:1504-10; PMID:19171174; http://dx.doi.org/10.1016/j.vaccine.2009.01.013
27. Johnstone J, Eurich DT, Minhas JK, Marrie TJ, Majumdar SR. Impact of the pneumococcal vaccine on long-term morbidity and mortality of adults at high risk for pneumonia. Clin Infect Dis 2010; 51(1):15-22; PMID:20504233; http://dx.doi.org/10.1086/653114
28. Conaty S, Watson L, Dinnes J, Waugh N. The effectiveness of pneumococcal polysaccharide vaccines in adults: a systematic review of observational studies and comparison with results from randomised controlled trials. Vaccine 2004; 22:3214-24; PMID:15297076; http://dx.doi.org/10.1016/j.vaccine.2003.08.050
29. Jackson LA, Neuzil KM, Yu O, Benson P, Barlow WE, Adams AL, Hanson CA, Mahoney LD, Shay DK, Thompson WW. Vaccine Safety Datalink. Effective- ness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003; 348:1747-55; PMID:12724480; http://dx.doi.org/10.1056/ NEJMoa022678
30. Vila-Corcoles A, Ochoa-Gondar O, Hospital I, Ansa X, Vilanova A, Rodrıguez T, Llor C. EVAN Study Group. Protective effects of the 23-Valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study. Clin Infect Dis 2006; 43:860-8; PMID:16941367; http://dx.doi.org/10.1086/507340
31. de Roux A, Schmole-Thoma B, Siber GR, Hackell JG, Kuhnke A, Ahlers N, Baker SA, Razmpour A, Emini EA, Fernsten PD, et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis 2008; 46:1015-23; PMID:18444818; http://dx.doi.org/10.1086/529142
32. Wiemken TL, Carrico RM, Klein SL, Jonsson CB, Peyrani P, Kelley RR, Aliberti S, Blasi F, Fernandez- Gonzalez R, Lopardo G, et al. CAPO Investigators. The effectiveness of the polysaccharide pneumococcal vaccine for the prevention of hospitalizations due to Streptococcus pneumonia community-acquired pneumonia in the elderly differs between the sexes: Results from the Community-Acquired Pneumonia Organization (CAPO) international cohort study. Vaccine 2014; 32:2198-203; PMID:24613522; http://dx.doi.org/10.1016/j.vaccine.2014.02.048
33. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997; 46(RR-8):24; PMID:9132580
34. Centers for Disease Control Prevention (CDC); Advisory Committee on Immunization Practices. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep 2010; 59:102-106; PMID:20134399
35. Lexau CA, Lynfield R, Danila R, Pilishvili T, Facklam R, Farley MM, Harrison LH, Schaffner W, Reingold A, Bennett NM, et al. Active bacterial core surveillance team. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005; 294:2043-2051; PMID:16249418; http://dx.doi.org/10.1001/jama.294.16.2043
36. Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008; (1): CD000422; PMID:18253977
37. Fisman DN, Abrutyn E, Spaude KA, Kim A, Kirchner C, Daley J. Prior pneumococcal vaccination is associated with reduced death, complications, and length of stay among hospitalized adults with community- acquired pneumonia. Clin Infect Dis 2006; 42(April 15):1093-101; PMID:16575726; http://dx.doi.org/10.1086/501354
38. Macintyre CR, Ridda I, Gao Z, Moa AM, McIntyre PB, Sullivan JS, Jones TR, Hayen A, Lindley RI. A randomized clinical trial of the immunogenicity of 7-Valent pneumococcal conjugate vaccine compared to 23-Valent polysaccharide vaccine in frail, hospitalized elderly. PLoS One 2014 Apr 23; 9(4):e94578; PMID:24760002; http://dx.doi.org/10.1371/journal. pone.0094578
39. Jackson LA, Gurtman A, van Cleeff M, Frenck RW, Treanor J, Jansen KU, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. Vaccine 2013 Aug 2; 31(35):3594-602; PMID:23688525; http://dx.doi.org/10.1016/j.vaccine.2013.04.084
40. Jackson LA, Gurtman A, van Cleeff M, Jansen KU, Jaya-wardene D, Devlin C, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine 2013 Aug 2; 31(35):3577-84; PMID:23688526; http://dx.doi.org/10.1016/j.vaccine.2013.04.085
41. Musher DM, Manof SB, Liss C, McFetridge RD, Marchese RD, Bushnell B, Alvarez F, Painter C, Blum MD, Silber JL. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults. J Infect Dis 2010; 201(4):516-24; PMID:20092407; http://dx. doi.org/10.1086/649839
42. Manoff SB, Liss C, Caulfield MJ, Marchese RD, Silber J, Boslego J, Romero-Steiner S, Rajam G, Glass NE, Whitney CG, et al. Revaccination with a 23-valent pneumococcal polysaccharide vaccine induces elevated and persistent functional antibody responses in adults aged >65 years. J Infect Dis 2010; 201(4):525-33; PMID:20088694; http://dx.doi.org/10.1086/651131
43. Nichol KL. Pneumococcal vaccination and revaccination in the elderly population. J Infect Dis 2010; 201:659-61; PMID:20113178; http://dx.doi.org/10.1086/651376
44. Musher DM, Rueda AM, Nahm MH, Graviss EA, Rodriguez-Barradas MC. Initial and subsequent response to pneumococcal polysaccharide and protein conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia. J Infect Dis 2008; 198(October 1):1019-27; PMID:18710324; http://dx.doi.org/10.1086/591629
45. Lazarus R, Clutterbuck E, Yu LM, Bowman J, Bateman EA, Diggle L, Angus B, Peto TE, Beverley PC, Mant D, et al. A randomized study comparing combined pneumococcal conjugate and polysaccharide vaccination schedules in adults. Clin Infect Dis 2011; 52 (6):736-42; PMID:21367726; http://dx.doi.org/10.1093/cid/cir003
46. Jackson LA, Neuzil KM, Nahm MH, Whitney CG, Yu O, Nelson JC, Starkovich PT, Dunstan M, Carste B, Shay DK, et al. Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 2007; 25(20):4029-37; PMID:17391816; http://dx.doi.org/10.1016/j.vaccine.2007.02.062
47. Goldblatt D, Southern J, Andrews N, Ashton L, Burbidge P, Woodgate S, Pebody R, Miller E. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years. Clin Infect Dis 2009; 49(9):1318-25; PMID:19814624; http://dx.doi.org/10.1086/606046
48. O’Brien KL, Hochman M, Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? Lancet Infect Dis 2007; 7(9):597-606; PMID:17714673; http://dx.doi.org/10.1016/S1473-3099(07)70210-4